Gain Therapeutics, Inc.
- GANX
- NASDAQ
- Biotechnology
- Rare Neurological Diseases
- Protein Misfolding Therapies
$1.26
Today −5.26%Quote Oct 16, 2026, 08:00 PM UTC
−29.21%over the last month
Max drawdown −35.4%From 1-month high −35.4%3 months −22.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$53.7M
Quote Oct 16
Next earnings
Nov 11
Expected, not confirmed
Analyst target
$5.00
+296.8% from here
Floor
$1.21
4.0% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GANXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
21